Purple Biotech Ltd (PPBT) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Reports Third Quarter 2024 Financial Results

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival...